Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
NEW YORK, Sept. 08, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Dr. Reddy’s Laboratories Ltd. ("Dr. Reddy’s") (NYSE:RDY) securities between June 17, 2015 and August 10, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/dr-reddys-laboratories-ltd?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India.
If you suffered a loss in Dr. Reddy’s you have until October 24, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/dr-reddys-laboratories-ltd?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
